|
1
|
Chen W, Mao K, Liu Z and Dinh-Xuan AT: The
role of the RhoA/Rho kinase pathway in angiogenesis and its
potential value in prostate cancer (Review). Oncol Lett.
8:1907–1911. 2014.(Review). PubMed/NCBI
|
|
2
|
Geus-Oei LF and Oyen WJ: Predictive and
prognostic value of FDG-PET. Cancer Imaging. 8:70–80. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Liu Y: Diagnostic role of
fluorodeoxyglucose positron emission tomography-computed tomography
in prostate cancer. Oncol Lett. 7:2013–2018. 2014.PubMed/NCBI
|
|
4
|
Risk MC, Knudsen BS, Coleman I, Dumpit RF,
Kristal AR, LeMeur N, Gentleman RC, True LD, Nelson PS and Lin DW:
Differential gene expression in benign prostate epithelium of men
with and without prostate cancer: evidence for a prostate cancer
field effect. Clin Cancer Res. 16:5414–5423. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chen XC, Yang DY and Che XY: Synthesis of
PSMA-targeted small molecule Glu-urea-Lys analogue. J Dalian Med
Univer. 34:13–17. 2012.
|
|
6
|
Silver DA, Pellicer I, Fair WR, Heston WD
and Cordon-Cardo C: Prostate-specific membrane antigen expression
in normal and malignant human tissues. Clin Cancer Res. 3:81–85.
1997.PubMed/NCBI
|
|
7
|
Rinnab L, Mottaghy FM, Blumstein NM, Reske
SN, Hautmann RE, Hohl K, Möller P, Wiegel T, Kuefer R and Gschwend
JE: Evaluation of [11C]-choline positron-emission/computed
tomography in patients with increasing prostate-specific antigen
levels after primary treatment for prostate cancer. BJU Int.
100:786–793. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ponde DE, Dence CS, Oyama N, Kim J, Tai
YC, Laforest R, Siegel BA and Welch MJ: 18F-fluoroacetate: A
potential acetate analog for prostate tumor imaging - in vivo
evaluation of 18F-fluoroacetate versus 11C-acetate. J Nucl Med.
48:420–428. 2007.PubMed/NCBI
|
|
9
|
Oka S, Hattori R, Kurosaki F, Toyama M,
Williams LA, Yu W, Votaw JR, Yoshida Y, Goodman MM and Ito O: A
preliminary study of
anti-1-amino-3-18F-fluorocyclobutyl-1-carboxylic acid for the
detection of prostate cancer. J Nucl Med. 48:46–55. 2007.PubMed/NCBI
|
|
10
|
Tehrani OS, Muzik O, Heilbrun LK, Douglas
KA, Lawhorn-Crews JM, Sun H, Mangner TJ and Shields AF: Tumor
imaging using
1-(2′-deoxy-2′-18F-fluoro-beta-D-arabinofuranosyl)thymine and PET.
J Nucl Med. 48:1436–1441. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Larson SM, Morris M, Gunther I, Beattie B,
Humm JL, Akhurst TA, Finn RD, Erdi Y, Pentlow K, Dyke J, et al:
Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone
versus 18F-FDG in patients with progressive, metastatic prostate
cancer. J Nucl Med. 45:366–373. 2004.PubMed/NCBI
|
|
12
|
Wang W and Mo ZN: Advances in
prostate-specific membrane antigen targeted therapies for prostate
cancer. Zhonghua Nan Ke Xue. 16:547–551. 2010.(In Chinese).
PubMed/NCBI
|
|
13
|
Rajasekaran SA, Anilkumar G, Oshima E,
Bowie JU, Liu H, Heston W, Bander NH and Rajasekaran AK: A novel
cytoplasmic tail MXXXL motif mediates the internalization of
prostate-specific membrane antigen. Mol Biol Cell. 14:4835–4845.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kim H, Shoji S, Tomonaga T, Shima M,
Terachi T and Uchida T: Prostate cancer with cyst formation
detected by whole body positron emission tomography/computed
tomography: A case report. Oncol Lett. 8:2037–2039. 2014.PubMed/NCBI
|
|
15
|
Tagawa ST, Beltran H, Vallabhajosula S,
Goldsmith SJ, Osborne J, Matulich D, Petrillo K, Parmar S, Nanus DM
and Bander NH: Anti-prostate-specific membrane antigen-based
radioimmunotherapy for prostate cancer. Cancer. 116:(Suppl).
1075–1083. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Maresca KP, Hillier SM, Femia FJ, Keith D,
Barone C, Joyal JL, Zimmerman CN, Kozikowski AP, Barrett JA,
Eckelman WC, et al: A series of halogenated heterodimeric
inhibitors of prostate specific membrane antigen (PSMA) as
radiolabeled probes for targeting prostate cancer. J Med Chem.
52:347–357. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pomper MG, Musachio JL, Zhang J, Scheffel
U, Zhou Y, Hilton J, Maini A, Dannals RF, Wong DF and Kozikowski
AP: 11C-MCG: Synthesis, uptake selectivity, and primate PET of a
probe for glutamate carboxypeptidase II (NAALADase). Mol Imaging.
1:96–101. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Foss CA, Mease RC, Fan H, Wang Y, Ravert
HT, Dannals RF, Olszewski RT, Heston WD, Kozikowski AP and Pomper
MG: Radiolabeled small-molecule ligands for prostate-specific
membrane antigen: In vivo imaging in experimental models of
prostate cancer. Clin Cancer Res. 11:4022–4028. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mease RC, Dusich CL, Foss CA, Ravert HT,
Dannals RF, Seidel J, Prideaux A, Fox JJ, Sgouros G, Kozikowski AP,
et al:
N-[N-[(S)-1,3-Dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine,
[18F]DCFBC: a new imaging probe for prostate cancer. Clin Cancer
Res. 14:3036–3043. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kularatne SA, Wang K, Santhapuram HK and
Low PS: Prostate-specific membrane antigen targeted imaging and
therapy of prostate cancer using a PSMA inhibitor as a homing
ligand. Mol Pharm. 6:780–789. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang AX, Murelli RP, Barinka C, Michel J,
Cocleaza A, Jorgensen WL, Lubkowski J and Spiegel DA: A remote
arene-binding site on prostate specific membrane antigen revealed
by antibody-recruiting small molecules. J Am Chem Soc.
132:12711–12716. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Qi Y, Zhang Q, Huang Y and Wang D:
Manifestations and pathological features of solitary thin-walled
cavity lung cancer observed by CT and PET/CT imaging. Oncol Lett.
8:285–290. 2014.PubMed/NCBI
|
